CITATION REPORT List of articles citing

Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene

DOI: 10.1126/science.2300823 Science, 1990, 247, 712-5.

Source: https://exaly.com/paper-pdf/21632430/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
569	A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. 1990 , 87, 6922-6		161
568	Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. 1990 , 87, 2775-9		463
567	Negative regulation of human c-fos expression by the retinoblastoma gene product. 1990 , 346, 668-71		29 0
566	Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides. 1990 , 5, 163-187		119
565	Autocrine regulation of cell growth and transformation by basic fibroblast growth factor. 1990 , 9, 191-	202	49
564	Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen <i>EMBO Journal</i> , 1990 , 9, 1815-1822	13	141
563	Recessive oncogenes in lung cancer. 1990 , 142, S44-7		8
562	Allelic loss of chromosomes 16q and 10q in human prostate cancer. 1990 , 87, 8751-5		404
561	Altered expression of the retinoblastoma gene product in human sarcomas. 1990 , 323, 1457-62		192
560	Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. 1990 , 87, 7762-6		279
559	Genetic mechanisms of tumor suppression by the human p53 gene. <i>Science</i> , 1990 , 250, 1576-80	33.3	478
558	Cancer genes: current status, future prospects, and applications in radiotherapy/oncology. 1990 , 19, 197-218		18
557	The retinoblastoma gene and cell growth control. 1990 , 15, 199-202		82
556	Through the looking glass: the discovery of supercoiled DNA. 1990 , 15, 202-7		14
555	TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. 1990 , 61, 777-85		550
554	Prostate cancer. 1990 , 27, 389-461		3
553	E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. 1991 , 113, 173	-85	1328

(1991-1991)

552	Tumor suppressor genes. <i>Science</i> , 1991 , 254, 1138-46	33.3	1346
551	HIV infection and gene transfer therapy. 1991 , 2, 111-2		5
550	Molecular genetics and human prostatic carcinoma. 1991 , 30, 181-5		22
549	Regulated expression of the RB "tumor suppressor gene" in normal lymphocyte mitogenesis: elevated expression in transformed leukocytes and role as a "status quo" gene. 1991 , 192, 289-97		13
548	Gene mapping in cancer. 1991 , 55, 139-47		1
547	The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. 1991 , 67, 293-302		667
546	Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. 1991 , 64, 521-32		527
545	Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. 1991 , 65, 25-35		487
544	G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. 1991 , 65, 381-93		298
543	The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. 1991 , 65, 1063-72		431
542	The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein. 1991 , 65, 1073-82		405
54 ¹	Molecular themes in oncogenesis. 1991 , 64, 235-48		1470
540	Tumor suppressor genes. 1991 , 64, 313-26		700
539	Gene therapy for cancer. 1991 , 27, 1069-70		7
538	Positive news on the negative growth factors. 1991 , 628, 1-8		2
537	Allelotyping of human prostatic adenocarcinoma. 1991 , 11, 530-6		133
536	Deletions and Rearrangements of the Retinoblastoma Gene in Hepatocellular Carcinoma, Insulinoma and Some Neurogenic Tumors as Found in a Study of 121 Tumors. 1991 ,		
535	Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase <i>EMBO Journal</i> , 1991 , 10, 857-864	13	204

534	Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. 1991 , 88, 10227-31		101
533	The retinoblastoma protein is phosphorylated on multiple sites by human cdc2 <i>EMBO Journal</i> , 1991 , 10, 4279-4290	13	229
532	Oncogenes and tumor-suppressor genes. 1991 , 93, 133-44		14
531	Control of junB and extracellular matrix protein expression by transforming growth factor-beta 1 is independent of simian virus 40 T antigen-sensitive growth-sensitive growth-inhibitory events. Molecular and Cellular Biology, 1991, 11, 972-8	4.8	94
530	Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. <i>Molecular and Cellular Biology</i> , 1991 , 11, 1745-50	4.8	84
529	Recessive oncogenes, antioncogenes and tumour suppression. 1991 , 47, 136-56		3
528	Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. <i>Molecular and Cellular Biology</i> , 1991 , 11, 4952-8	4.8	102
527	Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides. <i>Molecular and Cellular Biology</i> , 1991 , 11, 5792-9	4.8	139
526	Die Genetik urologischer Tumoren Teil 2: Klassische und zytogenetische Konzepte der Karzinogenese und chromosomale Aberrationen bei speziellen urologischen Tumoren. 1991 , 22, 1-9		10
525	Expression and interactions of human adenovirus oncoproteins. 1991 , 275 (Pt 2), 281-99		76
524	The genetics of retinoblastoma. Relevance to the patient. 1991 , 38, 299-315		40
523	A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product. 1991 , 350, 160-2		148
522	The current status of scientific research and hormonal treatments for carcinoma of the prostate. 1991 , 64, 419-21		7
521	Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. 1991 , 64, 475-80		58
520	Transformation effector and suppressor genes. 1991 , 46, 199-205		7
519	Identification of RB and p53 mutations in mouse lymphoma cell lines. 1991 , 4, 354-7		2
518	Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. 1991 , 46, 31-	6	82
517	Tumor suppressor genes: a new era for molecular genetic studies of cancer. 1991 , 19, 3-13		10

516	Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. 1991 , 19, 23-33		52
515	Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. 1991 , 10, 201-15		43
514	Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering. 1991 , 88, 3033-7		180
513	Positive selection of candidate tumor-suppressor genes by subtractive hybridization. 1991 , 88, 2825-9		272
512	The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. 1991 , 88, 5257-61		142
511	Expression of the Wilms' tumor gene WT1 in the murine urogenital system. 1991 , 5, 1345-56		350
510	The role of the retinoblastoma gene in breast cancer development. <i>Cancer Treatment and Research</i> , 1992 , 61, 59-68	3.5	17
509	Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. <i>Molecular and Cellular Biology</i> , 1991 , 11, 1-11	4.8	123
508	Regulation of prostate growth. 1991 , 131, 5-17		140
507	Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. 1991 , 88, 6662-6		97
506	Requirement of the adenovirus E1A transformation domain 1 for inhibition of PC12 cell neuronal differentiation. 1991 , 2, 479-89		29
505	Tumor Suppressor Genes: A Key to the Cancer Puzzle?. 1991 , 53, 22-24		3
504	Senescence of nickel-transformed cells by an X chromosome: possible epigenetic control. <i>Science</i> , 1991 , 251, 796-9	33.3	162
503	How do retinoblastoma tumours form?. 1992 , 6 (Pt 2), 226-31		16
502	Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F. <i>Molecular and Cellular Biology</i> , 1992 , 12, 5620-31	4.8	325
501	The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. 1992 , 6, 177-85		478
500	Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. 1992 , 89, 4549-53		526
499	Different DNA changes in primary and recurrent hepatocellular carcinoma. 1992 , 33, 1433-5		13

498	E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. <i>Science</i> , 1992 , 258, 424-9 33.3	1459
497	Identification of a growth suppression domain within the retinoblastoma gene product. 1992 , 6, 953-64	356
496	The retinoblastoma protein region required for interaction with the E2F transcription factor includes the T/E1A binding and carboxy-terminal sequences. 1992 , 11, 539-48	37
495	Nuclear protein phosphorylation and growth control. 1992 , 287 (Pt 1), 1-15	139
494	Editorial Comments. Journal of Urology, 1992, 147, 788-788	
493	Molecular genetics of tumor suppressor genes in prostate carcinoma: the challenge and the promise ahead. <i>Journal of Urology</i> , 1992 , 147, 808-9	9
492	Latent viruses and mutated oncogenes: no evidence for pathogenicity. 1992 , 43, 135-204	26
491	Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. 1992 , 89, 6599-603	76
490	Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. <i>Molecular and Cellular Biology</i> , 1992 , 12, 5363-72 ^{4.8}	147
489	The retinoblastoma gene product regulates Sp1-mediated transcription. <i>Molecular and Cellular Biology</i> , 1992 , 12, 2455-63	248
488	A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. 1992 , 89, 6010-4	48
487	Evidence for the involvement of protein kinase activity in transforming growth factor-beta signal transduction. <i>Molecular and Cellular Biology</i> , 1992 , 12, 261-5	73
486	Tumor suppressor genes in the cell cycle. 1992 , 4, 155-60	25
485	Role of local environmental factors in determining tissue-specific effects of estrogen: examination of uterine tissues transplanted to brain. 1992 , 87, 179-92	2
484	A European initiative for prostatic cancer. 1992 , 28A, 1937-8	
483	The retinoblastoma protein and the regulation of cell cycling. 1992 , 17, 312-5	159
482	Promotion as a factor in carcinogenesis. 1992 , 60, 1-9	14
481	The sometime suppressor gene RB 1. 1992 , 38, 259-60	1

480	The 'ins' and 'outs' of mitochondrial membrane channels. 1992 , 17, 315-20	86
479	Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. <i>Cancer Letters</i> , 1992 , 64, 257-63	26
478	Chromosomal abnormalities and related events in prostate cancer. 1992 , 23, 368-80	106
477	A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. 1992 , 70, 337-50	632
476	Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. 1992 , 70, 351-64	857
475	Cytogenetic and molecular studies of a familial renal cell carcinoma. 1992 , 63, 25-31	8
474	Genetics and cytogenetics of retinoblastoma. 1992 , 64, 1-11	38
473	Tumor-suppressor genes: cardinal factors in inherited predisposition to human cancers. 1992 , 98, 25-37	13
472	Co-deletions of the Retinoblastoma Gene and Wilms' Tumor Gene and Rearrangement of the Krev-1 Gene in a Human Insulinoma. 1992 ,	
471	Regulation of C-myc protooncogene expression in osteoblastic cells by arachidonic acid metabolites: relationship to proliferation. 1992 , 50, 372-7	6
470	Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. 1992 , 168, 23-8	68
469	Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. 1992 , 21, 145-52	41
468	The molecular biology of urological tumors. 1992 , 4, 159-69	6
467	Tumor suppressor genes: new pathways in gynecological cancer. 1992 , 2, 1-8	8
466	Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. 1992 , 359, 288-94	1159
465	Effects of an Rb mutation in the mouse. 1992 , 359, 295-300	1599
464	Abrogation by c-myc of G1 phase arrest induced by RB protein but not by p53. 1992 , 360, 177-9	94
463	Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. 1992 , 59, 1381-91	94

462	Bacterial assays for recombinagens. 1992 , 284, 125-46	12
461	Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer. 1992 , 110, 123-33	31
460	Spontaneous regression of cancer: new insights. 1992 , 4, 23-30	36
459	Tumour Suppressor Genes in Urinary Tract Oncology. 1992 , 70, 585-590	13
458	Tumor suppressor genes. 1992 , 14, 407-14	4
457	Transforming growth factor beta 1 as a biomarker for prostate cancer. 1992 , 16H, 54-61	59
456	Current and proposed biologic markers in prostate cancer. 1992 , 16H, 65-7	5
455	No alterations in exon 21 of the RB1 gene in sarcomas and carcinomas of the breast, colon, and lung. 1992 , 5, 97-103	10
454	Partial suppression of tumorigenicity in a human lung cancer cell line transfected with Krev-1. 1992 , 6, 252-9	8
453	Selection of appropriate cellular and molecular biologic diagnostic tests in the evaluation of cancer. 1992 , 69, 1607-32	29
452	Gene therapy of cancer through restoration of tumor-suppressor functions?. 1992 , 70, 1810-7	46
451	Transgenic models for the study of prostate cancer. 1993 , 71, 1165-71	35
450	Recessive oncogenes. 1993 , 71, 1179-86	26
449	How many mutations are required for tumorigenesis? Implications from human cancer data. 1993 , 7, 139-46	307
448	Negative regulation of mitogen-stimulated, anchorage-independent cell growth by a tumor-suppressor gene function. 1993 , 7, 249-56	3
447	Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. 1993 , 169, 405-12	46
446	Loss of constitutional heterozygosity on chromosomes 5 and 17 in cholangiocarcinoma. 1993 , 67, 1007-10	23
445	Molecular characterization of the retinoblastoma susceptibility gene. 1993 , 1155, 43-61	45

444	The retinoblastoma protein as a transcriptional repressor. 1993 , 3, 43-6		157
443	Human genetic therapy. 1993 , 14, 451-546		6
442	Tumor suppressor genes in urologic tumors. 1993 , 42, 461-6; discussion 466-7		8
441	Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. 1993 , 72, 309-24		693
440	A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. 1993 , 75, 779-90		378
439	Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. 1993 , 24, 4-9		152
438	Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. 1993 , 90, 985-9		236
437	Cationic Lipid/Polynucleotide Condensates for in Vitro and in Vivo Polynucleotide Delivery - the Cytofectins. 1993 , 3, 3-16		18
436	The retinoblastoma protein binds to a family of E2F transcription factors. <i>Molecular and Cellular Biology</i> , 1993 , 13, 7813-25	4.8	409
435	WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. <i>Science</i> , 1993 , 262, 2057-9	33.3	149
435		33:3	149
	1993, 262, 2057-9 TRANSFECTION OF THE MULLERIAN INHIBITING SUBSTANCE GENE INHIBITS LOCAL AND	33-3	149
434	1993, 262, 2057-9 TRANSFECTION OF THE MULLERIAN INHIBITING SUBSTANCE GENE INHIBITS LOCAL AND METASTATIC TUMOR-GROWTH. 1993, 2, 135	33.3	
434	TRANSFECTION OF THE MULLERIAN INHIBITING SUBSTANCE GENE INHIBITS LOCAL AND METASTATIC TUMOR-GROWTH. 1993 , 2, 135 Loss of heterozygosity - origin or result of carcinogenesis. 1993 , 2, 931-5	33.3	1
434 433 432	TRANSFECTION OF THE MULLERIAN INHIBITING SUBSTANCE GENE INHIBITS LOCAL AND METASTATIC TUMOR-GROWTH. 1993, 2, 135 Loss of heterozygosity - origin or result of carcinogenesis. 1993, 2, 931-5 Thymidine kinase-mediated killing of rat brain tumors. 1993, 79, 729-35	33.3	1 113
434 433 432 431	TRANSFECTION OF THE MULLERIAN INHIBITING SUBSTANCE GENE INHIBITS LOCAL AND METASTATIC TUMOR-GROWTH. 1993, 2, 135 Loss of heterozygosity - origin or result of carcinogenesis. 1993, 2, 931-5 Thymidine kinase-mediated killing of rat brain tumors. 1993, 79, 729-35 Gene therapy for cancer. 1993, 2, 367-72 The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. 1993,	33.3	1 113 1
434 433 432 431 430	TRANSFECTION OF THE MULLERIAN INHIBITING SUBSTANCE GENE INHIBITS LOCAL AND METASTATIC TUMOR-GROWTH. 1993, 2, 135 Loss of heterozygosity - origin or result of carcinogenesis. 1993, 2, 931-5 Thymidine kinase-mediated killing of rat brain tumors. 1993, 79, 729-35 Gene therapy for cancer. 1993, 2, 367-72 The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. 1993, 7, 555-69	33.3	1 113 1 1243

426 Suppression of anchorage-independent growth after gene transfection. **1993**, 68, 251-8

425	Structural and functional contributions to the G1 blocking action of the retinoblastoma protein. (the 1992 Gordon Hamilton Fairley Memorial Lecture). 1993 , 68, 264-8		19
424	p53 gene alterations in human prostate carcinoma. <i>Journal of Urology</i> , 1993 , 150, 257-61	2.5	88
423	E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. 1993 , 90, 6914-8		304
422	Adenocarcinoma of the prostate. Part II: Tissue prognosticators. 1993 , 100, 256-69		30
421	Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. <i>Molecular and Cellular Biology</i> , 1993 , 13, 6501-8	4.8	434
420	Overproduction of Rb protein after the G1/S boundary causes G2 arrest. <i>Molecular and Cellular Biology</i> , 1993 , 13, 6640-52	4.8	42
419	Human renal cancer carcinogenesis: a review of recent advances. 1993 , 4, 451-62		18
418	New prognostic factors in prostatic carcinoma. 1993 , 24, 438-49		23
417	Early diagnosis of prostatic carcinoma may be achieved through in vitro culture of tumor cells harvested by prostatic massage. 1993 , 24, 148-55		8
416	Expression of a retinoblastoma transgene results in dwarf mice. 1993 , 7, 1654-62		47
415	Ancient genomes, wise bodies, unhealthy people: limits of a genetic paradigm in biology and medicine. 1993 , 37, 112-45		77
414	Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences <i>EMBO Journal</i> , 1994 , 13, 4251-4259	13	213
413	Genetic Aberrations in Human Brain Tumors. <i>Neurosurgery</i> , 1994 , 34, 708-722	3.2	49
412	Expression of retinoblastoma gene in human intracranial neoplasms. 1994 , 4, 885-90		
411	Current status of prostate-cancer research - development of in-vitro model systems (review). 1994 , 5, 1233-42		1
410	The retinoblastoma gene and its significance. 1994 , 26, 177-84		18
409	Tumours in Urology. 1994 ,		

408	Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. 1994 , 8, 1300-10	235
407	Androgen signal transduction and prostatic carcinoma. 1994 , 12, 99-103	17
406	Tumor suppressor genes and their roles in breast cancer. 1994 , 32, 19-38	38
405	The cell cycle and the retinoblastoma protein family. 1994 , 13, 45-66	165
404	Does the human retinoblastoma gene have a role in colon cancer?. 1994 , 10, 1-7	13
403	Chromosome 13 transfer provides evidence for regulation of RB1 protein expression. 1994 , 9, 251-60	11
402	Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. 1994 , 58, 663-7	37
401	Role of the retinoblastoma protein in cell cycle arrest mediated by a novel cell surface proliferation inhibitor. 1994 , 55, 200-8	10
400	The transforming activity of simian virus 40 large tumor antigen. 1994 , 1198, 65-83	48
399	Retrovirus-mediated gene transfer in cancer therapy. 1994 , 63, 323-47	26
398	Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. 1994 , 70, 1252-7	120
397	Epigenesis: the missing beat in biotechnology?. 1994 , 12, 156-64	47
396	Recent advances in the molecular genetics of urogenital tumors. 1994 , 1, 1-16	9
395	The fraction of cells in G1 with bound retinoblastoma protein increases with the duration of the cell cycle. 1994 , 27, 95-104	5
394	Retinoblastoma protein monoclonal antibodies with novel characteristics. 1994 , 169, 231-40	15
393	The distal region of the long arm of human chromosome 1 carries tumor suppressor activity for a human fibrosarcoma line. 1994 , 73, 109-21	8
392	Oncogenes and cell death. 1994 , 4, 120-9	229
391	Inactivation of oncoprotein binding by a single Cys706-to-Tyr substitution in the retinoblastoma protein. 1994 , 340, 181-4	3

390	Gene replacement strategies for the prevention and therapy of cancer. 1994 , 30A, 2032-7		7
389	Differential immunohistochemical staining for retinoblastoma protein with the antibodies C15 and 1F8 in malignant mesothelioma. 1994 , 190, 138-41		4
388	Expression of p53 protein in prostate cancers of different histologic types. 1994 , 190, 384-8		7
387	Gene therapyits potential in the management of oral cancer. 1994 , 30B, 143-54		13
386	Effect of Restoration of Retinoblastoma Gene Function on the Radiosensitivity of Cells of Human Tumor Cell Lines. 1994 , 140, 172		5
385	Detection of Retinoblastoma Gene Deletions in Spontaneous and Radiation-Induced Mouse Lung Adenocarcinomas by Polymerase Chain Reaction. 1994 , 137, 310		7
384	The retinoblastoma tumor suppressor protein. 1994 , 64, 25-85		182
383	Proto-oncogenes and tumor suppressor genes in human urological malignancies. <i>Journal of Urology</i> , 1994 , 151, 1479-97	2.5	57
382	Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. 1994 , 91, 9837-41		48
381	The retinoblastoma gene product is a cell cycle-dependent, nuclear matrix-associated protein. 1994 , 91, 418-22		266
380	Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells. 1994 , 91, 4165-9		35
379	Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. 1994 , 51, 544-51		27
378	Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. 1995 , 92, 10436-40		88
377	Differential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins. <i>Molecular and Cellular Biology</i> , 1995 , 15, 3552-62	4.8	114
376	Retinoblastoma gene mutations in primary human bladder cancer. 1995 , 71, 831-5		62
375	The transcription factor E2F-1 is a downstream target of RB action. <i>Molecular and Cellular Biology</i> , 1995 , 15, 742-55	4.8	174
374	Basic principles associated with gene therapy of cancer. 1995 , 4, 125-37		4
373	Inactivation of retinoblastoma gene in malignant parathyroid growths: a candidate genetic trigger?. 1995 , 65, 714-6		22

372	Molecular genetics and chromosomal alterations in prostate cancer. 1995 , 75, 2004-2012	27
371	Murine models of neoplasia: functional analysis of the tumour suppressor genes Rb-1 and p53. 1995 , 14, 125-48	16
370	Oncogenes as inducers of tumor angiogenesis. 1995 , 14, 263-77	192
369	Transforming growth factor-beta and prostate cancer. 1995 , 13, 329-36	15
368	Interaction of viral and cellular proteins with the retinoblastoma tumour suppressor gene product. 1995 , 5, 97-103	3
367	Mini review: Molecular biology of prostate cancer. 1995 , 3, 353-357	
366	Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. 1995 , 26, 35-9	110
365	Retinoblastoma gene mutations in primary human prostate cancer. 1995 , 27, 314-20	87
364	Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas. 1995 , 133, 890-5	16
	Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial	
363	neoplastic progression. 1995 , 72, 683-90	75
363		75 2
	neoplastic progression. 1995 , 72, 683-90	
362	neoplastic progression. 1995 , 72, 683-90 Proto-oncogenes and oncogenes in epidermal neoplasia. 1995 , 4, 65-73	2
362 361	neoplastic progression. 1995 , 72, 683-90 Proto-oncogenes and oncogenes in epidermal neoplasia. 1995 , 4, 65-73 Gene therapy in surgical oncology. 1995 , 2, 179-88	2
362 361 360	neoplastic progression. 1995, 72, 683-90 Proto-oncogenes and oncogenes in epidermal neoplasia. 1995, 4, 65-73 Gene therapy in surgical oncology. 1995, 2, 179-88 Transcriptional control by the retinoblastoma protein. 1995, 6, 91-8	2 1 56
362 361 360 359	neoplastic progression. 1995, 72, 683-90 Proto-oncogenes and oncogenes in epidermal neoplasia. 1995, 4, 65-73 Gene therapy in surgical oncology. 1995, 2, 179-88 Transcriptional control by the retinoblastoma protein. 1995, 6, 91-8 Recessive oncogenes: current status. 1995, 1, 7-22	2 1 56 7
362 361 360 359 358	Proto-oncogenes and oncogenes in epidermal neoplasia. 1995, 4, 65-73 Gene therapy in surgical oncology. 1995, 2, 179-88 Transcriptional control by the retinoblastoma protein. 1995, 6, 91-8 Recessive oncogenes: current status. 1995, 1, 7-22 Molecular Genetics and Cytogenetics of Sarcomas. 1995, 9, 513-540 Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast	2 1 56 7 26

354	Dual retinoblastoma-binding proteins with properties related to a negative regulator of ras in yeast. 1995 , 270, 25507-13	116
353	Molecular cloning and characterization of the bovine and porcine outer dense fibers cDNA and organization of the bovine gene. 1995 , 376, 431-5	7
352	Multiple members of the E2F transcription factor family are the products of oncogenes. 1995 , 92, 1357-61	177
351	p53, Rb and bcl-2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microwave irradiated lymphoid tissue sections. 1995 , 48, 151-9	16
350	The role of decreased retinoblastoma protein expression in acute myelomonocytic and monoblastic leukemias. 1995 , 17, 135-7	3
349	Tumor suppressor genes and clonal evolution in B-CLL. 1995 , 18, 41-9	14
348	Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. 1995 , 16, 191-8	2
347	Abnormalities of retinoblastoma gene expression in hematological malignancies. 1995 , 18, 61-7	8
346	Advances in cancer gene therapy. 1995 , 32, 289-341	20
345	Stimulation of human insulin receptor gene expression by retinoblastoma gene product. 1995 , 270, 20525-9	16
344	PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. 1995 , 181, 1965-73	84
343	Detection of a novel cell cycle-regulated kinase activity that associates with the amino terminus of the retinoblastoma protein in G2/M phases. 1995 , 270, 9281-8	38
342	Disruption of retinoblastoma protein function by coexpression of its C pocket fragment. 1995 , 9, 31-46	79
341	Molecular insights into altered cell cycle regulation and genitourinary malignancy. 1995 , 1, 3-17	7
340	Expression of cyclin DI in human prostate cancer cell lines. 1995 , 1, 101-8	4
339	Loss of Heterozygosity Occurs Centromeric to RB Without Associated Abnormalities in the Retinoblastoma Gene in Tumors from Patients with Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 1995 , 153, 2050-2054	17
338	Absence of retinoblastoma gene product in human primary oral cavity carcinomas. 1996 , 32B, 347-51	21
337	Analysis of the retinoblastoma gene in human endometrial carcinoma. 1996 , 87, 755-9	8

[1996-1996]

336	Failure to detect mutations in the retinoblastoma protein-binding domain of the transcription factor E2F-1 in human cancers. 1996 , 87, 1204-9	4
335	Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. 1996 , 10, 2794-804	371
334	Antisense oncogene and tumor suppressor gene therapy of cancer. 1996 , 74, 191-204	18
333	Molecular oncology in pancreatic cancer. 1996 , 74, 313-20	28
332	ATF site of human RB gene promoter is a responsive element of myogenic differentiation. 1996 , 397, 219-24	13
331	Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. 1996 , 27, 28-34	74
330	How tumors become angiogenic. 1996 , 69, 135-74	348
329	Biomarker expression in prostatic intraepithelial neoplasia. 1996 , 30, 153-66	45
328	G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. 1996 , 93, 5941-6	58
327	The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. 1996 , 93, 9160-5	254
326	Hyperphosphorylation of retinoblastoma protein and stimulation of growth by okadaic acid in human pancreatic cancer. 1996 , 41, 1975-80	1
325	Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. 1996 , 1287, 103-20	70
324	Prostate cancer old problems and new approaches: Part I. epidemiology, incidence and genetic alterations. 1996 , 2, 98-109	2
323	Gene replacement strategies for lung cancer. 1996 , 6, 105-109	5
322	DNA methylation, molecular genetic, and linkage studies in prostate cancer. 1996 , 29, 36-44	22
321	p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. 1996 , 78, 17-23	44
320	Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. 1996 , 67, 16-9	35
319	Retinoblastoma protein family in cell cycle and cancer: A review. 1996 , 62, 418-430	145

318	Alterations of the retinoblastoma gene in human prostate adenocarcinoma. 1996, 15, 108-14	47
317	Molecular biology of prostate cancer. 1996 , 14, 318-28	28
316	Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/- mice. 1996 , 2, 1316-21	76
315	Immunohistochemical analysis of c-Fos and c-Jun in retinoblastoma. 1996 , 45, 289-91	
314	Absence of p16/MTS1 gene mutations in human prostate cancer. 1996 , 17, 2603-7	33
313	Genetic basis and clonal evolution of human prostate cancer. 1996 , 68, 225-55	45
312	Simian virus 40-, but not human papillomavirus-, transformation of prostatic epithelial cells results in loss of growth-inhibition by 1,25-dihydroxyvitamin D-3. 1996 , 8, 41-7	1
311	Detection of RB, p16/CDKN2 and p15(INK4B) gene alterations with immunohistochemical studies in human prostate carcinomas. 1996 , 8, 107-12	2
310	Cancer gene therapy and immunotherapy (review). 1996 , 9, 941-54	
309	Inhibition of B16 melanoma metastasis by the immunomodulator AS101. 1996 , 9, 319-25	1
309	Inhibition of B16 melanoma metastasis by the immunomodulator AS101. 1996 , 9, 319-25 Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. 1997 , 8, 177-85	1115
	Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander	
308	Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. 1997 , 8, 177-85	115
308	Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. 1997 , 8, 177-85 Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein. 1997 , 272, 5622-6	115 62
308 307 306	Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. 1997, 8, 177-85 Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein. 1997, 272, 5622-6 Two peptides derived from the nerve growth factor precursor are biologically active. 1997, 136, 389-98	115 62 32
308 307 306 305	Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. 1997, 8, 177-85 Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein. 1997, 272, 5622-6 Two peptides derived from the nerve growth factor precursor are biologically active. 1997, 136, 389-98 The p120-v-Abl protein interacts with E2F-1 and regulates E2F-1 transcriptional activity. 1997, 272, 8905-11 Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for	115 62 32 17
308 307 306 305 304	Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. 1997, 8, 177-85 Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein. 1997, 272, 5622-6 Two peptides derived from the nerve growth factor precursor are biologically active. 1997, 136, 389-98 The p120-v-Abl protein interacts with E2F-1 and regulates E2F-1 transcriptional activity. 1997, 272, 8905-11 Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells. 1997, 272, 22751-7 The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as	115 62 32 17 45

300	Tumor suppressor genes and human cancer. 1997 , 36, 45-135	24
299	Recent insights into the functions of the retinoblastoma susceptibility gene product. 1997 , 15, 243-54	39
298	Cytogenetics and molecular genetics in multiple myeloma. 1997 , 11, 1-25	39
297	Involvement of p53 and WAF1/CIP1 in gamma-irradiation-induced apoptosis of retinoblastoma cells. 1997 , 236, 51-6	26
296	Oncogenes and tumor suppressor genes in prostate cancer: a review. 1997 , 3, 41-6	14
295	Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands. 1997 , 3, 59-66	10
294	Analysis of retinoblastoma gene expression in human prostate tissue. 1997 , 3, 177-82	3
293	Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma. <i>American Journal of Human Genetics</i> , 1997 , 61, 556-70	80
292	Ionizing radiation and teniposide increase p21(waf1/cip1) and promote Rb dephosphorylation but fail to suppress E2F activity in MCF-7 breast tumor cells. 1997 , 52, 373-9	13
291	Tumour-suppressor genes in prostatic oncogenesis: a positional approach. 1997 , 79 Suppl 1, 28-36	44
290	Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. 1997 , 79 Suppl 1, 97-103	22
289	Altered Expression of the Retinoblastoma Tumor-Suppressor Gene in Leukemic Cell Lines Inhibits Induction of Differentiation But Not G1-Accumulation. 1997 , 89, 2938-2950	31
288	Concomitant presence of p16/cyclin-dependent kinase 4 and cyclin D/cyclin-dependent kinase 4 complexes in LNCaP prostatic cancer cell line. 1997 , 88, 229-33	19
287	Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. 1997 , 109, 61-8	15
286	Extensive analysis of the retinoblastoma gene in adult T cell leukemia/lymphoma (ATL). 1997, 11, 984-9	36
285	IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. 1997 , 14, 1165-70	79
284	Engineered mutants of pRB with improved growth suppression potential. 1997 , 15, 2855-66	11
283	Structural similarity between the pocket region of retinoblastoma tumour suppressor and the cyclin-box. 1997 , 4, 390-5	31

282	The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. 1997 , 246, 581-601	178
281	Genetic changes in prostate cancer. 1997 , 47, 735-47	18
280	Tumour suppressor genes in prostate cancer. 1997 , 8, 11-9	41
279	Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. 1997 , 30, 136-42	40
278	Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. 1998 , 391, 859-65	375
277	A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability. 1998 , 19, 371-4	48
276	The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties. 1998 , 16, 1973-9	60
275	E2F-1-induced p53-independent apoptosis in transgenic mice. 1998 , 17, 143-55	114
274	Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells. 1998 , 17, 1549-56	22
273	Introduction of a normal retinoblastoma (Rb) gene into Rb-deficient lymphoblastoid cells delays tumorigenicity in immunodefective mice. 1998 , 22, 905-12	3
272	E1A transformed normal human prostate epithelial cells contain a 16q deletion. 1998, 103, 155-63	5
271	IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. 1998 , 77, 138-45	32
270	Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. 1998 , 34, 145-51	24
269	Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. 1998 , 35, 95-101	63
268	Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. 1998 , 95, 617-24	38
267	Genetic aspects of prostate cancer. 1998 , 432, 389-406	34
266	Transcription by RNA polymerases I and III: a potential link between cell growth, protein synthesis and the retinoblastoma protein. 1998 , 76, 94-103	31
265	Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. 1998 , 34, 1575-81	58

Destruction of Human Cancers by an Altered Common Cold Virus. **1998**, 60, 408-410

263	Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. 1998 , 248, 361-7	109
262	Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo. 1998 , 63, 103-9	26
261	Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. 1998 , 139, 1197-207	193
260	RNA Polymerase III Transcription. 1998,	46
259	Expression level of G1-cyclins and cell proliferation in human cultured leukemia/lymphoma cell lines. 1998 , 12, 841-6	2
258	Nodular lesions of monocytic component in myelodysplastic syndrome. 1998 , 110, 154-62	18
257	Principles of transformation-directed cancer therapy. 1998 , 9-40	
256	Oncogene inactivation and replacement strategies for cancer. 1998 , 97-107	
255	Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. 1998 , 95, 5366-71	38
254	Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications. 1998 , 3, D997-D1004	17
253	Altered expression of retinoblastoma (RB) protein in acute myelogenous leukemia does not result from methylation of the Rb promotor. 1999 , 35, 283-8	9
252	Vitamin D and Prostate Cancer. 1999 , 221, 89-90	33
251	Molecular genetics and epidemiology of prostate carcinoma. 1999 , 20, 22-45	130
250	A paradigm for cancer treatment using the retinoblastoma gene in a mouse model. 1999 , 886, 12-22	5
249	Tumor-suppressive activity of CD66a in prostate cancer. 1999 , 6, 313-21	70
248	Frequent allelic loss of the RB, D13S319 and D13S25 locus in myeloid malignancies with deletion/translocation at 13q14 of chromosome 13, but not in lymphoid malignancies. 1999 , 13, 1367-73	22
247	Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. 1999 , 79, 551-7	34

246	Molecular analysis of selected cell cycle regulatory proteins during aerobic and hypoxic maintenance of human ovarian carcinoma cells. 1999 , 80, 1875-83	31
245	Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer. 1999 , 81, 342-9	6
244	Vitamin D and prostate cancer. 1999 , 221, 89-98	59
243	Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. 1999 , 72, 458-69	60
242	Interaction between the pRb2/p130 C-terminal domain and the N-terminal portion of cyclin D3. 1999 , 75, 698-709	7
241	Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. 1999 , 179, 336-46	62
240	Regulation of prostate cancer cell division by glucose. 1999 , 180, 431-8	54
239	Insights into cancer from transgenic mouse models. 1999 , 187, 43-60	93
238	Overexpression of cyclin D1 is rare in human prostate carcinoma. 1999 , 38, 40-5	40
237	Reversible tumorigenesis by MYC in hematopoietic lineages. 1999 , 4, 199-207	721
236	Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer. 1999 , 30, 809-15	27
235	Chapter 5 Molecular biology of prostate cancer. 1999 , 85-122	1
234	Chapter 8 Molecular progression of prostate cancer. 1999 , 3, 155-187	
233	Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein. <i>Molecular and Cellular Biology</i> , 1999 , 19, 3696-703	32
232	Growth factors and epithelial-stromal interactions in prostate cancer development. 2000, 199, 65-116	70
231	p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. 2000 , 19, 1297-306	34
230	Phosphorylation of the retinoblastoma-related protein p130 in growth-arrested cells. 2000 , 19, 5116-22	45
229	Asymmetry in 3-D perceptual organization: ground-like surface superior to ceiling-like surface. 2000 , 62, 540-9	33

228	Adenovirus p16 gene therapy for prostate cancer. 2000 , 18, 111-20	35
227	Role of pRB dephosphorylation in cell cycle regulation. 2000 , 5, D121-37	73
226	Antisense RNA-mediated deficiency of the calpain protease, nCL-4, in NIH3T3 cells is associated with neoplastic transformation and tumorigenesis. 2000 , 275, 31093-8	31
225	The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene. 2000 , 2, 161-9	18
224	Retinoblastoma expression in thyroid neoplasms. 2000 , 13, 562-9	34
223	Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. 2000 , 141, 10-7	159
222	C/EBPalpha inhibits cell growth via direct repression of E2F-DP-mediated transcription. <i>Molecular and Cellular Biology</i> , 2000 , 20, 5986-97	140
221	Neoplastic transformation and tumorigenesis associated with sam68 protein deficiency in cultured murine fibroblasts. 2000 , 275, 40195-201	45
220	Lack of RB protein correlates with increased sensitivity to UV-radiation-induced apoptosis in human breast cancer cells. 2000 , 154, 590-9	15
219	Selective inhibition of human lung cancer cell growth by peptides derived from retinoblastoma protein. 2000 , 267, 71-6	8
218	Molecular genetics of prostate cancer. 2000 , 14, 2410-34	492
217	G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. 2000 , 55, 316-22	13
216	The molecular biology of cancer. 2000 , 21, 167-223	290
215	Molecular mechanisms of cell cycle block by methionine restriction in human prostate cancer cells. 2000 , 38, 123-30	46
215	· · · · · · · · · · · · · · · · · · ·	48
	2000 , 38, 123-30	
214	QENE THERAPY FOR PROSTATE CANCER: WHERE ARE WE NOW?. <i>Journal of Urology</i> , 2000 , 164, 1121-113.69 pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell	48

210	Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. 2001 , 49, 224-33		41
209	Structural basis for the inactivation of retinoblastoma tumor suppressor by SV40 large T antigen. <i>EMBO Journal</i> , 2001 , 20, 295-304	13	129
208	Oncogenes and tumor suppressor genes in prostate cancer. 2001 , 23, 36-41		22
207	ANX7, a candidate tumor suppressor gene for prostate cancer. 2001 , 98, 4575-80		113
206	Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. 2001 , 69, 274-80		22
205	p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. 2002 , 13, 761-73		38
204	Nucleocytoplasmic shuttling of p130/RBL2: novel regulatory mechanism. <i>Molecular and Cellular Biology</i> , 2002 , 22, 453-68	4.8	58
203	Retinoblastoma protein-mediated apoptosis after gamma-irradiation. 2002 , 277, 44969-79		37
202	Rescue of embryonic epithelium reveals that the homozygous deletion of the retinoblastoma gene confers growth factor independence and immortality but does not influence epithelial differentiation or tissue morphogenesis. 2002 , 277, 44475-84		28
201	Steroid Hormones and Cell Cycle Regulation. 2002,		O
200	Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. <i>Molecular and Cellular Biology</i> , 2002 , 22, 8184-98	4.8	90
199	CDK inhibitors: cell cycle arrest versus apoptosis. 2002 , 1, 122-3		64
198	Vitamin D and prostate cancer. 2002 , 23, 9-17		62
197	Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. 2002 , 1574, 152-6		67
196	Rb localization and phosphorylation kinetics correlate with the cellular phenotype of cultured breast adenocarcinoma cells. 2002 , 38, 235-41		1
195	Interactions of SV40 large T antigen and other viral proteins with retinoblastoma tumour suppressor. 2002 , 12, 81-92		39
194	Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. 2002 , 51, 286-92		8
193	Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. 2002 , 53, 200-10		38

192	Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells. 2002 , 21, 4481-9	23
191	Development of Mammalian Somatic Cell Genetics. 2002 , 36, 251-258	
190	Cloning and expression of a novel retinoblastoma binding protein cDNA, RBBP10. 2002 , 40, 273-82	4
189	BCL-2 in prostate cancer: a minireview. 2003 , 8, 29-37	136
188	Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. 2003 , 88, 363-71	137
187	Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. 2003 , 195, 337-45	34
186	How the other half lives, the amino-terminal domain of the retinoblastoma tumor suppressor protein. 2003 , 197, 169-80	27
185	Allelic imbalance in hereditary and sporadic prostate cancer. 2003 , 54, 50-7	11
184	CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. 2003 , 88, 109-14	51
183	Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. 2003 , 100, 916-21	70
182	Transgenic mouse models for prostate cancer. Identification of an androgen-dependent promoter and creation and characterization of the long probasin promoter-Large T antigen (LPB-Tag) model. 2003 , 81, 113-47	5
181	. 2003,	7
180	Induction of androgen receptor-dependent apoptosis in prostate cancer cells by the retinoblastoma protein. 2004 , 64, 1377-85	19
179	Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. 2004 , 64, 6190-9	108
178	Molecular biology of prostate cancer. 2004 , 7, 6-20	35
177	Human prostate cancer risk factors. 2004 , 101, 2371-490	409
176	Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. 2004 , 39, 114-26	94
175	Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation. 2004 , 59, 219-27	23

174	Role of the RB tumor suppressor in cancer. <i>Cancer Treatment and Research</i> , 2003 , 115, 209-39 3.5	65
173	Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C. 2005 , 24, 6256-68	166
172	Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. 2005 , 38, 50-7	63
171	Prostate cancer and the genomic revolution: Advances using microarray analyses. 2005 , 576, 66-79	16
170	Gene transfer therapy in cancer. 1993 , 80, 566-72	24
169	Immunochemical analysis of protein expression in breast epithelial cells transformed by estrogens and high linear energy transfer (LET) radiation. 2005 , 124, 261-74	12
168	GENE THERAPY FOR PROSTATE CANCER. 2005 , 75-105	
167	Gene Therapy ITumour-suppressor Gene Replacement/Oncogene Suppression. 2005,	
166	Molecular pathology of prostate cancer. 2005 , 58, 673-84	91
165	Genetically engineered murine models of prostate cancer: insights into mechanisms of tumorigenesis and potential utility. 2005 , 1, 351-60	17
164	Regulation of growth and differentiation in Dictyostelium. 2005, 244, 287-332	31
163	Cell Cycle Genes: pRb and p53. 2005 , 339-379	
162	Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells. 2005 , 337, 498-504	15
161	Future innovations in treating advanced prostate cancer. <i>Urologic Clinics of North America</i> , 2006 , 33, 247-72, viii	3
160	Cancer of the Prostate: Molecular Genetics. 2006,	
159	Immunohistochemical detection of retinoblastoma protein and E2 promoter-binding factor-1 in ameloblastomas. 2006 , 35, 183-9	20
158	Overexpression of PKCepsilon sensitizes LNCaP human prostate cancer cells to induction of apoptosis by bryostatin 1. 2006 , 118, 1572-6	16
157	Protein phosphatase 1alpha activity prevents oncogenic transformation. 2006 , 45, 648-56	15

(2009-2006)

156	Hypoxia increases androgen receptor activity in prostate cancer cells. 2006 , 66, 5121-9	66
155	Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. 2006 , 66, 7889-98	226
154	Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. 2006 , 103, 15540-5	159
153	Prostate Cancer. 2006,	
152	RbAp48 is a critical mediator controlling the transforming activity of human papillomavirus type 16 in cervical cancer. 2007 , 282, 26381-91	34
151	Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus. 2007 , 70, 1243-8	11
150	Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. 2007 , 26, 1028-37	92
149	Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. 2008, 3, 64-8	77
148	Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. 2008 , 7, 1828-35	47
147	Targeting prostate cancer based on signal transduction and cell cycle pathways. 2008 , 7, 1745-62	80
146	Distinct roles for p107 and p130 in Rb-independent cellular senescence. 2008 , 7, 1262-8	15
145	CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. 2008, 100, 940-9	144
144	The extreme COOH terminus of the retinoblastoma tumor suppressor protein pRb is required for phosphorylation on Thr-373 and activation of E2F. 2008 , 295, C1151-60	11
143	Retinoblastoma in Humans and Animals. 2008 , 305-336	1
142	Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin. 2009 , 12, 8-14	39
141	p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. 2009 , 69, 1166-73	55
140	Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells. 2009 , 125, 2528-39	21
139	Role of protein kinase C-iota in transformed non-malignant RWPE-1 cells and androgen-independent prostate carcinoma DU-145 cells. 2009 , 42, 182-94	16

138	Novel functions of ribosomal protein S6 in growth and differentiation of Dictyostelium cells. 2009 , 51, 533-46	3
137	Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. 2009 , 61, 572-88	28
136	Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity. <i>Cancer Letters</i> , 2009 , 285, 166-73	42
135	Regulation and function of retinoblastoma-related plant genes. 2009 , 177, 540-548	23
134	Rb family proteins in gastric cancer (review). 2010 , 24, 1411-8	13
133	Cell-cycle checkpoint for transition from cell division to differentiation. 2011 , 53, 463-81	13
132	3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. 2011 , 50, 100-12	42
131	Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. 2011, 8, 562-8	31
130	Rb1/105 gene alterations and head and neck carcinogenesis. 2012 , 39, 9573-81	2
129	The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. 2012 , 72, 3764-74	78
128	Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor. 2012 , 103, 2139-43	9
127	Prostate Cancer. 2013 ,	5
126	Vitamin D and Prostate Cancer. 2013 , 421-442	
125	The impaired viability of prostate cancer cell lines by the recombinant plant kallikrein inhibitor. 2013 , 288, 13641-54	12
124	The top 100 cited articles in urology. 2009 , 3, 293-302	97
123	PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. 2013 , 8, e60408	82
122	The top 100 cited articles in urology: An update. 2013 , 7, 16	36
121	Hyperactivated Wnt signaling induces synthetic lethal interaction with Rb inactivation by elevating TORC1 activities. 2014 , 10, e1004357	14

120	Identification and genetic analysis of cancer cells with PCR-activated cell sorting. 2014, 42, e128	46
119	Cytotoxic effects of escin on human castration-resistant prostate cancer cells through the induction of apoptosis and G2/M cell cycle arrest. 2014 , 84, 982.e1-7	23
118	RbAp48 Is Critical for the Proliferation of Hypopharyngeal Carcinoma. 2015 , 77, 310-9	2
117	NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells. 2015 , 75, 517-26	31
116	miR-449a enhances radiosensitivity through modulating pRb/E2F1 in prostate cancer cells. 2016 , 37, 4831-40	25
115	"Researching the Research" in Prostate Cancer: A Comparative Bibliometric Analysis of the Top 100 Cited Articles in the Field of Prostate Cancer. 2017 , 11, 26-35	7
114	Encyclopedia of Signaling Molecules. 2018 , 4497-4497	
113	Encyclopedia of Signaling Molecules. 2018 , 4699-4699	
112	Encyclopedia of Signaling Molecules. 2018 , 4752-4752	
111	Encyclopedia of Signaling Molecules. 2018 , 4433-4438	
110	The Genomics of Prostate Cancer: emerging understanding with technologic advances. 2018, 31, S1-11	31
109	DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. 2018 , 71, 592-605.e4	75
108	The Prognostic Value of G1 Cyclins, p21 and Rb Protein in Patients With Colon Cancer. 2019 , 39, 6291-6297	6
107	The Genomics of Prostate Cancer: A Historic Perspective. 2019 , 9,	10
106	Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion. 2020 , 39, 5690-5707	3
105	Autophagy and PTEN in DNA damage-induced senescence. 2021 , 150, 249-284	O
104	Novel insights in cell cycle dysregulation during prostate cancer progression. 2021 , 28, R141-R155	3
103	Gene therapy of cancer through restoration of tumor-suppressor functions?. 1992 , 70, 1810-1817	24

102	Transgenic models for the study of prostate cancer. 1993 , 71, 1165-1171		32
101	Regulation of epithelial proliferation by TGF-beta. 1991 , 157, 66-74; discussion 75-80		6
100	Biological considerations in lung cancer. Cancer Treatment and Research, 2001, 105, 1-30	3.5	5
99	The role of human papillomavirus in the genesis of cervical cancer. <i>Cancer Treatment and Research</i> , 1994 , 70, 29-41	3.5	6
98	Genetic aspects of cancer. 1993 , 21, 321-76		10
97	Oncogenes in human lung cancer. Cancer Treatment and Research, 1992, 63, 61-85	3.5	13
96	Cytogenetic and molecular genetic aspects of human prostate cancer: primary and metastatic. 1992 , 324, 45-75		6
95	Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. 1997 , 407, 41-53		46
94	Transgenic Mouse Models of Prostate Cancer. 2001 , 401-425		3
93	The Molecular Basis of Prostate Carcinogenesis. 2002 , 365-378		1
92	Molecular Dissection of the Prostate Cancer Genome. 2003 , 25-40		2
91	Molecular Genetics in Carcinoma of the Bladder. 1998 , 37-51		4
90	Multiple Genetic Alterations and Abnormal Growth Factor Network in Human Esophageal Carcinomas. 1997 , 31-41		1
89	Growth Factor Expression in Breast Tissue. 1991 , 53-60		2
88	The Male Reproductive System: Prostatic Cell Lines. 1994 , 387-411		4
87	Biochemistry of Prostatic Carcinoma. 1994 , 169-237		5
86	The Cyclin/Cyclin-Dependent Kinase (cdk) Complex. 1997 , 145-174		2
85	Vitamin D and Prostate Cancer. 2005 , 1679-1707		8

84	Identification of a p53 binding site in the human retinoblastoma susceptibility gene promoter 1994 , 269, 6383-6389		36
83	Functional analysis at the Cys706 residue of the retinoblastoma protein 1992 , 267, 25998-26003		20
82	EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line 1992 , 267, 2714-2722		77
81	v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines 1993 , 268, 23460-23468		218
80	Physiologic Basis of Endocrine Therapy for Prostatic Cancer. <i>Urologic Clinics of North America</i> , 1991 , 18, 1-13	2.9	39
79	A review of tumor suppressor genes in cutaneous neoplasms with emphasis on cell cycle regulators. 1998 , 20, 302-13		11
78	Oncogenes, malignant transformation, and modern medicine. 1990 , 300, 59-69		8
77	Human gene therapy. 1991 , 301, 353-63		43
76	GENE THERAPY FOR PROSTATE CANCER: WHERE ARE WE NOW?. Journal of Urology, 2000, 1121-1136	2.5	3
75	Binding of p53 and p105-RB is not sufficient for oncogenic transformation by a hybrid polyomavirus-simian virus 40 large T antigen. <i>Journal of Virology</i> , 1990 , 64, 5250-9	6.6	41
74	Activity of the simian virus 40 early promoter-enhancer in herpes simplex virus type 1 vectors is dependent on its position, the infected cell type, and the presence of Vmw175. <i>Journal of Virology</i> , 1991 , 65, 6900-12	6.6	20
73	Simian virus 40 can overcome the antiproliferative effect of wild-type p53 in the absence of stable large T antigen-p53 binding. <i>Journal of Virology</i> , 1991 , 65, 4160-8	6.6	20
7 ²	Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. <i>Journal of Virology</i> , 1991 , 65, 4966-72	6.6	68
71	Dissociation of retinoblastoma gene protein hyperphosphorylation and commitment to enter S phase. <i>Journal of Virology</i> , 1994 , 68, 3724-32	6.6	12
70	An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. <i>Journal of Virology</i> , 1995 , 69, 6249-58	6.6	154
69	E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. <i>Journal of Virology</i> , 1995 , 69, 2491-500	6.6	333
68	Constitutive retinoid receptors expressed from adenovirus vectors that specifically activate chromosomal target genes required for differentiation of promyelocytic leukemia and teratocarcinoma cells. <i>Journal of Virology</i> , 1996 , 70, 7182-9	6.6	6
67	Perturbation of the p53 response by human papillomavirus type 16 E7. <i>Journal of Virology</i> , 1997 , 71, 3710-8	6.6	41

66	Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. <i>Molecular and Cellular Biology</i> , 1991 , 11, 1-11	4.8	37
65	Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. <i>Molecular and Cellular Biology</i> , 1991 , 11, 4952-4958	4.8	25
64	Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides. <i>Molecular and Cellular Biology</i> , 1991 , 11, 5792-5799	4.8	67
63	Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. <i>Molecular and Cellular Biology</i> , 1991 , 11, 1745-1750	4.8	19
62	Evidence for the involvement of protein kinase activity in transforming growth factor-beta signal transduction. <i>Molecular and Cellular Biology</i> , 1992 , 12, 261-265	4.8	15
61	Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. <i>Molecular and Cellular Biology</i> , 1992 , 12, 5363-5	3 7 2	74
60	Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F. <i>Molecular and Cellular Biology</i> , 1992 , 12, 5620-56	34 ⁸	150
59	The retinoblastoma gene product regulates Sp1-mediated transcription. <i>Molecular and Cellular Biology</i> , 1992 , 12, 2455-2463	4.8	92
58	Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. <i>Molecular and Cellular Biology</i> , 1993 , 13, 6501-6508	4.8	201
57	Overproduction of Rb protein after the G1/S boundary causes G2 arrest. <i>Molecular and Cellular Biology</i> , 1993 , 13, 6640-6652	4.8	19
56	The retinoblastoma protein binds to a family of E2F transcription factors. <i>Molecular and Cellular Biology</i> , 1993 , 13, 7813-7825	4.8	178
55	Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. <i>Circulation</i> , 1997 , 96, 1899-905	16.7	47
54	Deficiency of coagulation factor XIII A subunit caused by the dinucleotide deletion at the 5' end of exon III. <i>Journal of Clinical Investigation</i> , 1992 , 90, 315-9	15.9	26
53	Targeted tumor killing via an intracellular antibody against erbB-2. <i>Journal of Clinical Investigation</i> , 1995 , 96, 2980-9	15.9	76
52	Genetic aberrations in human brain tumors. <i>Neurosurgery</i> , 1994 , 34, 708-22	3.2	61
51	In vitro p53 and/or Rb antisense oligonucleotide treatment in association with growth factors induces the proliferation of peripheral hematopoietic progenitors. <i>Journal of Cell Science</i> , 1995 , 108, 1287-1293	5.3	7
50	Advances in genetics: widening our understanding of prostate cancer. F1000Research, 2016, 5,	3.6	2
49	miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. <i>Oncotarget</i> , 2010 , 1, 349-58	3.3	129

(1995-2003)

48	THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. II. PRODUCTS OF SUPPRESSOR GENES RB AND PTEN, CDKI, FAS. 1.7 2 Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2003, 147, 11-17
47	Molecular Genetics and Markers of Progression. 2000 , 47-70
46	A Biological Framework for the Development of Therapy in Prostate Cancer. 2000 , 189-201
45	Antiproliferative Effect of Vitamin D in Prostate Epithelial Cells. 2002 , 173-190
44	Prostatakarzinom. 2004 , 1233-1266
43	Suppression of the Phenotype of T24 H-ras1 Transformed Cells. 1991 , 145-151
42	Genetische Grundlagen der Tumor- und Metastasensuppression bei Drosophila und Mensch. 1991 , 51-61
41	Molekulare und funktionelle Untersuchung von Tumor-Suppressorgenen. <i>Verhandlungen Der Deutschen Gesellschaft Fi</i> Neurologie, 1991 , 346-347
40	Future Developments of Nonhormonal Systemic Therapy for Prostatic Carcinoma. <i>Urologic Clinics of North America</i> , 1991 , 18, 25-33
39	Control of junB and extracellular matrix protein expression by transforming growth factor-beta 1 is independent of simian virus 40 T antigen-sensitive growth-sensitive growth-inhibitory events. 4.8 31 Molecular and Cellular Biology, 1991, 11, 972-978
38	A Potential Approach to Gene Therapy of Cancer. Research and Perspectives in Neurosciences, 1992, 20-27
37	Growth Regulatory Networks in the Prostate. 1992 , 51-66
36	Genetische Schritte in Zusammenhang mit der Entstehung des Prostatakarzinoms. 1993 , 151-165
35	Biochemistry of Prostate Cancer. 1994 , 145-161
34	Benign and malignant prostatic neoplasms: human studies. <i>Endocrine Reviews</i> , 1994 , 49, 293-331
33	Tumour Suppressor Genes in Hodgkin Disease. 1995 , 209-222
32	Potential Clinical Significance of the p53 Tumor Suppressor Gene in Cancer Patients. <i>Molecular Biology Intelligence Unit</i> , 1995 , 113-125
31	Das Prostatakarzinom: Wissenschaftliche Grundlagen und Behandlung. 1995 , 33-37

30	Andere fildas Prostata-Screening interessante Marker. 1995 , 149-165		
29	Loss of Heterozygosity Occurs Centromeric to RB Without Associated Abnormalities in the Retinoblastoma Gene in Tumors from Patients with Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 1995 , 2050-2054	2.5	1
28	Tumor Suppressor Genes and Oncogenes in Human Prostate Cancer. 1996 , 395-414		
27	Retinoblastoma gene in malignancy. Cancer Treatment and Research, 1996, 84, 261-77	3.5	1
26	Carcinoma of the Prostate: Science and Treatment. 1996 , 31-35		
25	Neoplastic Transformation: Oncogenes, Tumor Suppressors, Cyclins, and Cyclin-Dependent Kinases. 1996 , 3-41		
24	Total androgen blockade for prostate cancer: the end does not justify the means. <i>Cancer Treatment and Research</i> , 1996 , 88, 201-10	3.5	
23	Progression of LNCaP Human Prostate Carcinoma Cells: Androgen Receptor Activity and c-myc Gene Expression. 1996 , 260-268		
22	Molekularbiologie und Genetik urogenitaler Tumoren. 1997 , 783-841		
21	References. 1997 , 215-326		
20	Intracellular Antibody-Mediated Knockout of the ErbB-2 Oncoprotein as a Cancer Gene Therapy Approach. 1998 , 97-128		
19	Encyclopedia of Signaling Molecules. 2016 , 1-4		
18	Conclusion. 2016 , 253-257		
17	Encyclopedia of Signaling Molecules. 2017 , 1-4		
16	Encyclopedia of Signaling Molecules. 2018 , 4642-4645		
15	Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. <i>EMBO Journal</i> , 1994 , 13, 4251-9	13	92
14	Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. <i>EMBO Journal</i> , 1991 , 10, 857-64	13	106
13	The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. <i>EMBO Journal</i> , 1991 , 10, 4279-90	13	130

CITATION REPORT

12	Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. <i>EMBO Journal</i> , 1990 , 9, 1815-22	13	74
11	Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. <i>American Journal of Human Genetics</i> , 1991 , 48, 880-8	11	304
10	Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. <i>American Journal of Pathology</i> , 1995 , 147, 545-60	5.8	317
9	Image analysis quantitation of immunoreactive retinoblastoma protein in human thyroid neoplasms with a streptavidin-biotin-peroxidase staining technique. <i>American Journal of Pathology</i> , 1991 , 139, 1213-9	5.8	23
8	Expression of the retinoblastoma protein is regulated in normal human tissues. <i>American Journal of Pathology</i> , 1994 , 144, 500-10	5.8	58
7	Prostate cancer progression. Implications of histopathology. <i>American Journal of Pathology</i> , 1994 , 145, 983-93	5.8	31
6	Implication of gelatinases in retinoblastoma development. <i>Romanian Journal of Ophthalmology</i> , 2016 , 60, 68-70	1	
5	Tumor specifically internalizing peptide HN-1日Targeting the putative receptor retinoblastoma-regulated discoidin domain receptor 1 involved in metastasis. <i>World Journal of Clinical Oncology</i> , 2022 , 13, 323-338	2.5	
4	Modeling prostate cancer: What does it take to build an ideal tumor model?. <i>Cancer Letters</i> , 2022 , 543, 215794	9.9	1
3	Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of 田2AX foci. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 409-416	6.1	11
2	Enhancing the diversity of self-replicating structures using active self-adapting mechanisms. <i>Frontiers in Genetics</i> , 13,	4.5	
1	Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. 2022 , 13,		1